Earnings Call · Q4 FY2024·2025-03-03

Q4 24EPS -100.00%*·Rev n/aQ3 24EPS +7.55%·Rev n/aQ2 24EPS +12.09%·Rev n/aQ1 24EPS +13.27%·Rev n/a⚠ consensus missing

Syndax Pharmaceuticals Inc SNDX

Sharon Klahre — Head of Investor Relations

Michael Metzger — Chief Executive Officer

Steve Closter — Commercial/Launch Executive

Neil Gallagher — Executive involved in development program

Keith Goldan — Chief Financial Officer

−1.0%1d on move date+0.7% vs SPY3d−7.4%5d−14.2%

Research tier

Behavioral profile computed for 5 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more SNDX calls or request research access.

More SNDX calls Browse calls Request research access